The Zhitong Finance App learned that on Monday, Moderna (MRNA.US) stock price fell. As of press release, the stock had fallen more than 4% to 92.44 US dollars. Previously, HSBC downgraded Moderna's rating from “holding” to “reducing holdings” and was cautious about the overall market potential of Moderna's mRNA vaccine. The company's maximum sales are expected to be US$1.7 billion, which is at the lower end of the agreed expected range of US$1.5 billion to US$2.4 billion.